Literature DB >> 2565889

The biliary elimination of the selective beta-receptor blocking drug talinolol in man.

B Terhaag1, T Gramatté, K Richter, J Voss, K Feller.   

Abstract

The biliary elimination of the beta-1-receptor blocking agent talinolol was investigated after intravenous administration of 30 mg in 6 patients with a T-tube drain after cholecystectomy. Serum concentration decreased in a biexponential manner with a median terminal half-life time of 4.4 h (range: 3.0-6.2 h). In some patients a second peak of the serum level was found. Concentration-time curves in bile paralleled serum profiles. The bile:serum concentration ratio (b:s-ratio) ranged from 24 to 98. The biliary clearance amounted to 43 ml/h.kg (range: 13-212 ml/h.kg). The median of the amount of talinolol eliminated by bile was 2.8 mg (range: 1.1-7.4 mg). It is concluded that talinolol undergoes an enterohepatic circulation. However, the amount eliminated cannot provide a sufficient explanation for the second peak, observed in some patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2565889

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  9 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

2.  In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.

Authors:  Marija Tubic; Daniel Wagner; Hilde Spahn-Langguth; Michael B Bolger; Peter Langguth
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

3.  The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen.

Authors:  Werner Weitschies; Annika Bernsdorf; Thomas Giessmann; Michael Zschiesche; Christiane Modess; Vera Hartmann; Claudia Mrazek; Danilo Wegner; Stefan Nagel; Werner Siegmund
Journal:  Pharm Res       Date:  2005-05-17       Impact factor: 4.200

4.  Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo.

Authors:  U Wetterich; H Spahn-Langguth; E Mutschler; B Terhaag; W Rösch; P Langguth
Journal:  Pharm Res       Date:  1996-04       Impact factor: 4.200

5.  Interaction of talinolol and sulfasalazine in the human gastrointestinal tract.

Authors:  B Terhaag; U Palm; H Sahre; K Richter; R Oertel
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

6.  Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.

Authors:  Annika Bernsdorf; Thomas Giessmann; Christiane Modess; Danilo Wegner; Stefanie Igelbrink; Ute Hecker; Sierk Haenisch; Ingolf Cascorbi; Bernd Terhaag; Werner Siegmund
Journal:  Br J Clin Pharmacol       Date:  2006-04       Impact factor: 4.335

7.  Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers.

Authors:  He Juan; Bernd Terhaag; Zang Cong; Zhang Bi-Kui; Zhu Rong-Hua; Wang Feng; Su Fen-Li; Song Juan; Tang Jing; Peng Wen-Xing
Journal:  Eur J Clin Pharmacol       Date:  2007-04-28       Impact factor: 3.064

8.  Sex-, feeding-, and circadian time-dependency of P-glycoprotein expression and activity - implications for mechanistic pharmacokinetics modeling.

Authors:  Alper Okyar; Swati A Kumar; Elisabeth Filipski; Enza Piccolo; Narin Ozturk; Helena Xandri-Monje; Zeliha Pala; Kristin Abraham; Ana Rita Gato de Jesus Gomes; Mehmet N Orman; Xiao-Mei Li; Robert Dallmann; Francis Lévi; Annabelle Ballesta
Journal:  Sci Rep       Date:  2019-07-19       Impact factor: 4.379

Review 9.  Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies.

Authors:  Mohamed Elmeliegy; Manoli Vourvahis; Cen Guo; Diane D Wang
Journal:  Clin Pharmacokinet       Date:  2020-06       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.